Intersect ENT Inc. (XENT)
NASDAQ: XENT
· Real-Time Price · USD
28.24
0.00 (0.00%)
At close: Apr 24, 2025, 3:47 PM
Intersect ENT Revenue Breakdown
| Period Ending | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Propel Family Of Products Revenue | 18.9M | 26.75M | 20.87M | 23.06M | 20.44M | 24.71M | 21.05M | 299K | 736K | 1.35M | 1.09M | 1.1M |
| Propel Family Of Products Revenue Growth | -29.32% | +28.16% | -9.49% | +12.80% | -17.28% | +17.40% | +6940.47% | -59.38% | -45.64% | +23.77% | -0.18% | n/a |
| Sinuva Revenue | 868K | 1.97M | 1.98M | 2.69M | 2.44M | 2.61M | 1.67M | n/a | n/a | n/a | n/a | n/a |
| Sinuva Revenue Growth | -56.01% | -0.35% | -26.28% | +10.31% | -6.74% | +56.44% | n/a | n/a | n/a | n/a | n/a | n/a |
| VenSure, CUBE, And Accessories Revenue | 1.8M | 1.95M | 1.55M | 1.6M | 1.45M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| VenSure, CUBE, And Accessories Revenue Growth | -7.58% | +25.94% | -3.37% | +10.54% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2021 |
|---|---|
| Europe Revenue | 400K |
| Europe Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 28.03M | 35.79M | 29.47M | 28.73M | 28.08M | 31.15M | 21.7M | 19.5M | 26.2M | 27.23M | 26.43M | 27.61M | 27.21M | 26.32M | 22.76M | 21M | 21.52M | 22.3M | 18.75M | 18.68M | 20.32M | 19.83M | 17.91M | 17.8M | 17.39M | 16.48M | 16.42M | 14.12M | 12.62M |
| Selling, General, and Administrative Revenue Growth | -21.68% | +21.42% | +2.58% | +2.33% | -9.87% | +43.54% | +11.31% | -25.58% | -3.79% | +3.04% | -4.28% | +1.48% | +3.36% | +15.65% | +8.36% | -2.37% | -3.51% | +18.95% | +0.34% | -8.06% | +2.45% | +10.77% | +0.62% | +2.31% | +5.54% | +0.37% | +16.31% | +11.86% | n/a |
| Research and Development Revenue | 9.39M | 8.49M | 6.72M | 6.36M | 6.37M | 5.63M | 4.55M | 4.02M | 5.15M | 5.83M | 6.14M | 6.04M | 6.27M | 5.74M | 4.87M | 4.37M | 4.27M | 5.62M | 4.35M | 4.18M | 4.22M | 5.57M | 4.24M | 4.59M | 4.5M | 4.45M | 4.8M | 4.04M | 3.33M |
| Research and Development Revenue Growth | +10.59% | +26.43% | +5.64% | -0.16% | +13.04% | +23.82% | +13.27% | -21.92% | -11.75% | -5.11% | +1.72% | -3.59% | +9.11% | +17.88% | +11.39% | +2.36% | -23.94% | +29.27% | +4.07% | -1.04% | -24.24% | +31.46% | -7.65% | +2.07% | +1.12% | -7.38% | +18.85% | +21.41% | n/a |